The common patatin-like phospholipase domain–containing protein 3 (PNPLA3) variant I148M predisposes to nonalcoholic liver disease but not its metabolic sequelae. We compared the handling of labeled polyunsaturated fatty acids (PUFAs) and saturated fatty acids (SFA) in vivo in humans and in cells harboring different PNPLA3 genotypes. In 148M homozygous individuals, triglycerides (TGs) in very low–density lipoproteins (VLDL) were depleted of PUFAs both under fasting and postprandial conditions compared with 148I homozygotes, and the PUFA/SFA ratio in VLDL-TGs was lower relative to the chylomicron precursor pool. In human PNPLA3-148M and PNPLA3-KO cells, PUFA but not SFA incorporation into TGs was increased at the expense of phosphatidylcholines, and under lipolytic conditions, PUFA-containing diacylglycerols (DAGs) accumulated compared with PNPLA3-148I cells. Polyunsaturated TGs were increased, while phosphatidylcholines (PCs) were decreased in the human liver in 148M homozygous individuals as compared with 148I homozygotes. We conclude that human PNPLA3-I148M is a loss-of-function allele that remodels liver TGs in a polyunsaturated direction by impairing hydrolysis/transacylation of PUFAs from DAGs to feed phosphatidylcholine synthesis.
Panu K. Luukkonen, Auli Nick, Maarit Hölttä-Vuori, Christoph Thiele, Elina Isokuortti, Susanna Lallukka-Brück, You Zhou, Antti Hakkarainen, Nina Lundbom, Markku Peltonen, Marju Orho-Melander, Matej Orešič, Tuulia Hyötyläinen, Leanne Hodson, Elina Ikonen, Hannele Yki-Järvinen
Title and authors | Publication | Year |
---|---|---|
Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
Pei Y, Goh GB |
Gut and Liver | 2025 |
FSP1-mediated lipid droplet quality control prevents neutral lipid peroxidation and ferroptosis
Lange M, Wölk M, Doubravsky CE, Hendricks JM, Kato S, Otoki Y, Styler B, Nakagawa K, Fedorova M, Olzmann JA |
bioRxiv | 2025 |
Ketogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation
Queathem ED, Moazzami Z, Stagg DB, Nelson AB, Fulghum K, Hayir A, Seay A, Gillingham JR, d\u2019Avignon DA, Han X, Ruan HB, Crawford PA, Puchalska P |
Science Advances | 2025 |
Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver disease
Coyne ES, Nie Y, Lee D, Pandovski S, Yang T, Zhou H, Rosahl TW, Carballo-Jane E, Abdurrachim D, Zhou Y, Hendra C, Ali AA, Meyers S, Blumenschein W, Gongol B, Liu Y, Zhou Y, Talukdar S |
Hepatology Communications | 2025 |
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies
Bourganou MV, Chondrogianni ME, Kyrou I, Flessa CM, Chatzigeorgiou A, Oikonomou E, Lambadiari V, Randeva HS, Kassi E |
International Journal of Molecular Sciences | 2025 |
The Intersection of Genetic Factors, Aberrant Nutrient Metabolism and Oxidative Stress in the Progression of Cardiometabolic Disease
Butcko AJ, Putman AK, Mottillo EP |
Antioxidants | 2024 |
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model
van Riet S, Julien A, Atanasov A, Nordling Å, Ingelman-Sundberg M |
Hepatology Communications | 2024 |
Exploring the impact of lipid droplets on the evolution and progress of hepatocarcinoma.
Maurotti S, Geirola N, Frosina M, Mirarchi A, Scionti F, Mare R, Montalcini T, Pujia A, Tirinato L |
Frontiers in Cell and Developmental Biology | 2024 |
PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein
Johnson SM, Bao H, McMahon CE, Chen Y, Burr SD, Anderson AM, Madeyski-Bengtson K, Lindén D, Han X, Liu J |
Nature Communications | 2024 |
Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity
Tas E, Sundararajan D, Lo JS, Morelli N, Garcia-Reyes Y, Ware MA, Rahat H, Ou X, Na X, Sundaram S, Severn C, Pyle LL, Børsheim E, Vajravelu ME, Muzumdar R, Dranoff JA, Cree MG |
Journal of the Endocrine Society | 2024 |
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
Bril F, Kalavalapalli S, Lomonaco R, Frye R, Godinez Leiva E, Cusi K |
2024 | |
Dysfunctional VLDL metabolism in MASLD
Marigorta UM, Millet O, Lu SC, Mato JM |
2024 | |
Heterocyclic Amines Disrupt Lipid Homeostasis in Cryopreserved Human Hepatocytes.
Walls KM, Joh JY, Hong KU, Hein DW |
Cardiovascular Toxicology | 2024 |
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy
Xia M, Varmazyad M, Pla-Palacín I, Gavlock DC, DeBiasio R, LaRocca G, Reese C, Florentino RM, Faccioli LA, Brown JA, Vernetti LA, Schurdak M, Stern AM, Gough A, Behari J, Soto-Gutierrez A, Taylor DL, Miedel MT |
Frontiers in Cell and Developmental Biology | 2024 |
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD.
Sun B, Ding X, Tan J, Zhang J, Chu X, Zhang S, Liu S, Zhao Z, Xuan S, Xin Y, Zhuang L |
Clinical and molecular hepatology | 2024 |
Metabolomics at the cutting edge of risk prediction of MASLD
Tan EY, Muthiah MD, Sanyal AJ |
Cell Reports Medicine | 2024 |
Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk
Castanho Martins M, Dixon ED, Lupo G, Claudel T, Trauner M, Rombouts K |
Liver International | 2024 |
Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis
Ye Tian, Matthew Jellinek, Kritika Mehta, Sun Seok, Shanny Kuo, Wei Lu, Ruicheng Shi, Richard Lee, Gee Lau, Jongsook Kemper, Kai Zhang, David Ford, Bo Wang |
Hepatology | 2023 |
Genome Editing and Fatty Liver.
Hayat U, Siddiqui AA, Farhan ML, Haris A, Hameed N |
Advances in experimental medicine and biology | 2023 |
Lipid droplets and polyunsaturated fatty acid trafficking: Balancing life and death
Danielli M, Perne L, Jarc Jovičić E, Petan T |
Frontiers in Cell and Developmental Biology | 2023 |
Nutritional Genomics in Nonalcoholic Fatty Liver Disease
Vasconcellos C, Ferreira O, Lopes MF, Ribeiro AF, Vasques J, Guerreiro CS |
Biomedicines | 2023 |
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis.
Hendriks D, Brouwers JF, Hamer K, Geurts MH, Luciana L, Massalini S, López-Iglesias C, Peters PJ, Rodríguez-Colman MJ, Chuva de Sousa Lopes S, Artegiani B, Clevers H |
Nature Biotechnology | 2023 |
Hepatic Phospholipid Remodeling Modulates Insulin Sensitivity and Systemic Metabolism
Tian Y, Mehta K, Jellinek MJ, Sun H, Lu W, Shi R, Ingram K, Friedline RH, Kim JK, Kemper JK, Ford DA, Zhang K, Wang B |
Advanced Science | 2023 |
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
Alonso-Peña M, Del Barrio M, Peleteiro-Vigil A, Jimenez-Gonzalez C, Santos-Laso A, Arias-Loste MT, Iruzubieta P, Crespo J |
International journal of molecular sciences | 2023 |
Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.
Tian Y, Wang B |
Journal of Gastroenterology and Hepatology | 2023 |
Insulin Regulation of Hepatic Lipid Homeostasis
Uehara K, Santoleri D, Whitlock AE, Titchenell PM |
Comprehensive Physiology | 2023 |
Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.
Tai J, Hsu CW, Chen WT, Yang SS, Chiu CH, Chien RN, Chang ML |
Cancer Science | 2023 |
Postprandial plasma lipidomics reveal specific alteration of hepatic-derived diacylglycerols in non-alcoholic fatty liver disease
T Velenosi, G Ben-Yakov, M Podszun, J Hercun, O Etzion, S Yang, C Nadal, V Haynes-Williams, W Huang, L Gonzalez-Hodar, R Brychta, S Takahashi, V Akkaraju, K Krausz, M Walter, H Cai, P Walter, R Muniyappa, K Chen, F Gonzalez, Y Rotman |
Gastroenterology | 2022 |
Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis
K Uehara, J Sostre-Colón, M Gavin, D Santoleri, K Leonard, R Jacobs, P Titchenell |
CMGH Cellular and Molecular Gastroenterology and Hepatology | 2022 |
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
A Gatzios, M Rombaut, K Buyl, J Kock, R Rodrigues, V Rogiers, T Vanhaecke, J Boeckmans |
Biomedicines | 2022 |
Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms
Hudert CA, Adams LA, Alisi A, Anstee QM, Crudele A, Draijer LG, Furse S, Hengstler JG, Jenkins B, Karnebeek K, Kelly DA, Koot BG, Koulman A, Meierhofer D, Melton PE, Mori TA, Snowden SG, van Mourik I, Vreugdenhil A, Wiegand S, Mann JP |
Hepatology Communications | 2022 |
IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
Park J, Zhao Y, Zhang F, Zhang S, Kwong AC, Zhang Y, Hoffmann HH, Bushweller L, Wu X, Ashbrook AW, Stefanovic B, Chen S, Branch AD, Mason CE, Jung JU, Rice CM, Wu X |
Journal of Hepatology | 2022 |
Decreased Hyocholic Acid and Lysophosphatidylcholine Induce Elevated Blood Glucose in a Transgenic Porcine Model of Metabolic Disease.
Xu J, Zhang K, Qiu B, Liu J, Liu X, Yang S, Xiao X |
Metabolites | 2022 |
Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration.
Peloso A, Tihy M, Moeckli B, Rubbia-Brandt L, Toso C |
Nutrients | 2022 |
Mapping transcriptional heterogeneity and metabolic networks in fatty livers at single-cell resolution
Coassolo L, Liu T, Jung Y, Taylor NP, Zhao M, Charville GW, Nissen SB, Yki-Jarvinen H, Altman RB, Svensson KJ |
iScience | 2022 |
Human hepatocyte PNPLA3 148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice
Kabbani M, Michailidis E, Steensels S, Fulmer CG, Luna JM, Pen JL, Tardelli M, Razooky B, Ricardo-Lax I, Zou C, Zeck B, Stenzel AF, Quirk C, Foquet L, Ashbrook AW, Schneider WM, Belkaya S, Lalazar G, Liang Y, Pittman M, Devisscher L, Suemizu H, Theise ND, Chiriboga L, Cohen DE, Copenhaver R, Grompe M, Meuleman P, Ersoy BA, Rice CM, de Jong YP |
Cell reports | 2022 |
Modeling PNPLA3 ‐Associated NAFLD Using Human‐Induced Pluripotent Stem Cells
SG Tilson, CM Morell, AS Lenaerts, SB Park, Z Hu, B Jenkins, A Koulman, TJ Liang, L Vallier |
Hepatology | 2021 |
TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion
J Hsieh, MM Molusky, KM McCabe, P Fotakis, T Xiao, L Tascau, L Zeana-Schliep, P DaSilva-Jardine, AR Tall |
Journal of Hepatology | 2021 |
Metabolic drivers of non-alcoholic fatty liver disease
KK Bence, MJ Birnbaum |
Molecular Metabolism | 2021 |
Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
DG Mashek |
Molecular Metabolism | 2021 |
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
K Pafili, M Roden |
Molecular Metabolism | 2021 |
Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice
M Tardelli, FV Bruschi, CD Fuchs, T Claudel, N Auer, V Kunczer, OA Ronda, HJ Verkade, T Stojakovic, H Scharnagl, M Trauner |
International journal of molecular sciences | 2021 |
Metabolic-associated fatty liver disease and lipoprotein metabolism
J Heeren, L Scheja |
Molecular Metabolism | 2021 |
Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives
M Dallio, M Romeo, AG Gravina, M Masarone, T Larussa, L Abenavoli, M Persico, C Loguercio, A Federico |
Nutrients | 2021 |
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
O Juanola, S Martínez-López, R Francés, I Gómez-Hurtado |
International journal of environmental research and public health | 2021 |
Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases
SA Dabravolski, EE Bezsonov, MS Baig, TV Popkova, AN Orekhov |
International journal of molecular sciences | 2021 |
Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk
SA Dabravolski, EE Bezsonov, MS Baig, TV Popkova, LV Nedosugova, AV Starodubova, AN Orekhov |
International journal of molecular sciences | 2021 |
Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics
J Jiao, SY Kwan, CM Sabotta, H Tanaka, L Veillon, MO Warmoes, PL Lorenzi, Y Wang, P Wei, ET Hawk, JL Almeda, JB McCormick, SP Fisher-Hoch, L Beretta |
Cancer epidemiology, biomarkers & prevention | 2021 |
A Study of Blood Fatty Acids Profile in Hyperlipidemic and Normolipidemic Subjects in Association with Common PNPLA3 and ABCB1 Polymorphisms
T Mouskeftara, A Goulas, D Ioannidou, C Ntenti, D Agapakis, A Assimopoulou, H Gika |
Metabolites | 2021 |
Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
AD Sessa, S Riccio, E Pirozzi, M Verde, AP Passaro, GR Umano, S Guarino, EM del Giudice, P Marzuillo |
World journal of gastroenterology : WJG | 2021 |
Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico
YN Flores, AT Amoon, B Su, R Velazquez-Cruz, P Ramírez-Palacios, J Salmerón, B Rivera-Paredez, JS Sinsheimer, AJ Lusis, A Huertas-Vazquez, S Saab, BA Glenn, FP May, KJ Williams, R Bastani, SJ Bensinger |
Lipids in Health and Disease | 2021 |
Genetics Is of the Essence to Face NAFLD
M Meroni, M Longo, G Tria, P Dongiovanni |
Biomedicines | 2021 |
A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes
CV Schneider, KM Schneider, DM Conlon, J Park, M Vujkovic, I Zandvakili, YA Ko, C Trautwein, RM Carr, P Strnad, CA Thaiss, DJ Rader |
The American Journal of Medicine | 2021 |
Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis
BA Banini, DP Kumar, S Cazanave, M Seneshaw, F Mirshahi, PK Santhekadur, L Wang, HP Guan, AM Oseini, C Alonso, P Bedossa, SV Koduru, HK Min, AJ Sanyal |
Hepatology | 2021 |
Nonalcoholic fatty liver disease stratification by liver lipidomics
Vvedenskaya O, Rose TD, Knittelfelder O, Palladini A, Wodke JA, Schuhmann K, Ackerman JM, Wang Y, Has C, Brosch M, Thangapandi VR, Buch S, Züllig T, Hartler J, Köfeler HC, Röcken C, Coskun Ü, Klipp E, von Schoenfels W, Gross J, Schafmayer C, Hampe J, Pauling JK, Shevchenko A |
Journal of lipid research | 2021 |
Abdominal Fat and Metabolic Health Markers but Not PNPLA3 Genotype Predicts Liver Fat Accumulation in Response to Excess Intake of Energy and Saturated Fat in Healthy Individuals
F Rosqvist, M Orho-Melander, J Kullberg, D Iggman, HE Johansson, J Cedernaes, H Ahlström, U Risérus |
Frontiers in Nutrition | 2020 |
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
C Rives, A Fougerat, S Ellero-Simatos, N Loiseau, H Guillou, L Gamet-Payrastre, W Wahli |
Biomolecules | 2020 |
Insights into genetic variants associated with NASH-fibrosis from metabolite profiling
JP Mann, M Pietzner, LB Wittemans, ED Rolfe, ND Kerrison, F Imamura, NG Forouhi, E Fauman, ME Allison, JL Griffin, A Koulman, NJ Wareham, C Langenberg |
Human Molecular Genetics | 2020 |
Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
PK Luukkonen, S Dufour, K Lyu, XM Zhang, A Hakkarainen, TE Lehtimäki, GW Cline, KF Petersen, GI Shulman, H Yki-Järvinen |
Proceedings of the National Academy of Sciences | 2020 |
Perspectives on youth‐onset nonalcoholic fatty liver disease
E CastilloLeon, CE Cioffi, MB Vos |
2020 | |
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
N Perakakis, K Stefanakis, CS Mantzoros |
Metabolism | 2020 |
Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD
E Vilar-Gomez, CJ Pirola, S Sookoian, LA Wilson, P Belt, T Liang, W Liu, N Chalasani |
The American Journal of Gastroenterology | 2020 |
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis
B Carlsson, D Lindén, G Brolén, M Liljeblad, M Bjursell, S Romeo, R Loomba |
Alimentary Pharmacology & Therapeutics | 2020 |
Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity
E Tas, S Bai, X Ou, K Mercer, H Lin, K Mansfield, R Buchmann, EC Diaz, J Oden, E Børsheim, SH Adams, J Dranoff |
Frontiers in Endocrinology | 2020 |
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
A Deprince, JT Haas, B Staels |
Molecular Metabolism | 2020 |
Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology
S Sookoian, CJ Pirola, L Valenti, NO Davidson |
Hepatology | 2020 |
The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease
M Tardelli, FV Bruschi, M Trauner |
Hepatology | 2020 |
Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using “Good-Fit” Genome-Editing Tools
U Kim, N Kim, HY Shin |
Cells | 2020 |
PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver
L Yuan, NA Terrrault |
Hepatobiliary surgery and nutrition | 2020 |